Generation of two isogenic-corrected control cell lines (IRMBi001-A-1; IRMBi001-A-2) from Autosomal dominant Alzheimer’s disease patient-derived iPSCs carrying a G217D mutation in presenilin 1 gene

Mutations in the preselinin1 (PSEN1) gene are responsible for rare autosomic dominant Alzheimer's disease (ADAD). We generated isogenic control cell lines from iPS cell line derived from ADAD patient carrying a G217D mutation in PSEN1 gene, with CRISPR Cas9 technology. The edited cell lines present the correction of the c.650G > A mutation, no chromosomal abnormalities and no evidence of off-target event. The IRMBi001-A-1 and IRMBi001-A-2 cell lines exhibit pluripotency markers expression and the ability to differentiate into the three germ layers. These two isogenic controls will be used as control to study the pathomechanistic of ADAD through various in vitro assays.

Authors

Institutions

Publication Details

Journal
Stem Cell Research
Published
2025-07-19
DOI
https://doi.org/10.1016/j.scr.2025.103780
Primary Topic
Computational Drug Discovery Methods
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Generation of two isogenic-corrected control cell lines (IRMBi001-A-1; IRMBi001-A-2) from Autosomal dominant Alzheimer’s disease patient-derived iPSCs carrying a G217D mutation in presenilin 1 gene

Coralie Clua Provost, Sylvain Lehmann, David Wallon, Carole Crozet et al.
Stem Cell Research
Computational Drug Discovery Methods
article

Generation of two isogenic-corrected control cell lines (IRMBi001-A-1; IRMBi001-A-2) from Autosomal dominant Alzheimer’s disease patient-derived iPSCs carrying a G217D mutation in presenilin 1 gene

Coralie Clua Provost, Sylvain Lehmann, David Wallon, Carole Crozet, C. Monzo, Valentin Garcia, Emmanuel Nivet, Louise Greetham, Arnaud Monteil, Hélène Hirbec, Anne Rovelet‐Lecrux
article en

Abstract

Mutations in the preselinin1 (PSEN1) gene are responsible for rare autosomic dominant Alzheimer's disease (ADAD). We generated isogenic control cell lines from iPS cell line derived from ADAD patient carrying a G217D mutation in PSEN1 gene, with CRISPR Cas9 technology. The edited cell lines present the correction of the c.650G > A mutation, no chromosomal abnormalities and no evidence of off-target event. The IRMBi001-A-1 and IRMBi001-A-2 cell lines exhibit pluripotency markers expression and the ability to differentiate into the three germ layers. These two isogenic controls will be used as control to study the pathomechanistic of ADAD through various in vitro assays.

Stem Cell ResearchVol. 87
Centre National de la Recherche Scientifique (FR), Siriraj Hospital (TH), Inserm (FR), Université de Montpellier (FR), Institut de Neurophysiopathologie (FR), Normandie Université (FR), Institute for Neurosciences of Montpellier (FR), Institut de Génomique Fonctionnelle (FR), Université de Rouen Normandie (FR)
Good health and well-being
Openalex Percentile: Top 80%
Computational Drug Discovery Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Generation of two isogenic-corrected control cell lines (IRMBi001-A-1; IRMBi001-A-2) from Autosomal dominant Alzheimer’s disease patient-derived iPSCs carrying a G217D mutation in presenilin 1 gene — Coralie Clua Provost, Sylvain Lehmann, et al. · Stem Cell Research (2025) | TGRS Research Map | TGRS